Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
314 studies found for:    colorectal | Recruiting | Exclude Unknown | United States
Show Display Options
Rank Status Study
1 Recruiting Ohio Colorectal Cancer Prevention Initiative
Conditions: Lynch Syndrome;   Colorectal Cancer
Interventions: Genetic: LS tumor screening;   Genetic: Genetic testing;   Behavioral: Genetic Counseling;   Other: Biorepository;   Behavioral: Questionnaire
2 Recruiting Decision Aid to Technologically Enhance Shared Decision Making
Condition: Colorectal Cancer
Intervention: Behavioral: Colorectal Web
3 Recruiting Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease (IBD);   Primary Sclerosing Cholangitis (PSC);   Colorectal Neoplasms;   Colorectal Cancer
Intervention:
4 Recruiting Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)
Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy;   Procedure: FIT
5 Recruiting Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Conditions: Colorectal Cancer;   Colon Polyps;   Adenomatous Polyp of Colon
Intervention:
6 Recruiting A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: PF-05212384;   Drug: irinotecan;   Drug: Cetuximab;   Drug: Irinotecan
7 Recruiting Adjuvant Aflibercept for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Aflibercept
8 Recruiting Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab;   Drug: Cetuximab
9 Recruiting ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Conditions: Appendix Cancer;   Colorectal Cancer
Interventions: Procedure: Cytoreductive Surgery;   Drug: HIPEC with Mitomycin-C;   Drug: EPIC with FUDR and Leucovorin
10 Recruiting Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Conditions: Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C/NEO-102
11 Recruiting Study of Ruxolitinib in Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Ruxolitinib;   Drug: Regorafenib;   Drug: Placebo
12 Recruiting COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
13 Recruiting FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Interventions: Drug: FOLFOX6m;   Device: SIR-Spheres microspheres
14 Recruiting Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: LGX818;   Drug: Cetuximab;   Drug: BYL719
15 Recruiting A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
Condition: Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions: Drug: PledOx (2 µmol/kg);   Drug: PledOx (5 µmol/kg);   Drug: Placebo (0,9% NaCl)
16 Recruiting Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer;   Colon Cancer;   Rectal Cancer
Intervention: Drug: IMMU-130
17 Recruiting CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2
Conditions: Solid Tumors;   Melanoma;   Metastatic Colorectal Cancer
Intervention: Drug: CEP-32496
18 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
19 Recruiting Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: Neratinib
20 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Lynch Syndrome
Interventions: Drug: Naproxen;   Other: Placebo;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years